All Posts
Blog
ASCO Releases Statement on Recommendations to Improve Accessibility to Cancer Clinical Trials
August 14, 2024 9:00 amby Kyle Doherty
A research statement was published by the American Society of Clinical Oncology (ASCO) that describes 4 recommendations for decentralization to improve accessibility of cancer clinical trials.1,2
In the statement, the ASCO panel recommended that the FDA … Read more
‘Symptom triggered’ testing can pick up early-stage aggressive ovarian cancer in 1 in 4 of those affected
August 13, 2024 9:00 amby University of Birmingham
A study published in the International Journal of Gynecological Cancer found that the UK’s protocol for picking up early-stage disease in women with high grade serous ovarian cancer—the most common, aggressive, and lethal form of the … Read more
Review Highlights the Need to Increase Germline BRCA Mutation Testing in Males
August 12, 2024 9:00 amby Jax DiEugenio
Although the risks of cancer developing in females harboring germline BRCA1or BRCA2 mutations are understood and have propelled genetic testing and preventative measures for this population, more work is required to amplify the rates of this … Read more
Study Finds Higher Rates of Hereditary Cancer Mutations in Minority Populations Missed by Current Screening Guidelines
July 24, 2024 9:00 amby IPM staff
A new study from the Mayo Clinic finds that current screening protocols fail to catch a significant number of individuals with genetic mutations linked to hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome, which increase … Read more
Focused Radiation Is Safe, Effective for Metastatic Gynecologic Cancer Stereotactic ablative radiotherapy led to promising disease control in patients with metastatic gynecologic cancers, research showed.
July 22, 2024 9:00 am by Brielle Benyon
Stereotactic ablative radiotherapy (SABR) can be a promising and tolerable way to control gynecologic cancers, according to research published in JAMA Oncology.
SABR is a type of radiation that is highly focused. It provides an intense … Read more
Landmark Study Shows Elevated Cancer Risk for Women with Endometriosis
July 17, 2024 9:00 amby Huntsman Cancer Institute at the University of Utah
Newswise — A landmark study from researchers at Huntsman Cancer Institute at the University of Utah (the U), the Spencer Fox Eccles School of Medicine at the U, and Boston University … Read more
Stigmas About Palliative Care Are Harming Our Seriously Ill Patients
July 10, 2024 9:00 amby Stephen “Fred” Divers, MD, Chief Medical Officer & Julia Frydman, MD, Medical Director for Palliative Care
“I wish we had done this sooner.” This is something that we hear a lot from our patients and their families when they … Read more
From Educator to Advocate – Connie’s Story
July 10, 2024 9:00 amClearity Perspective: When people like Connie share their ovarian cancer experience, it helps others learn about resources and feel less alone. Connie speaks about how she benefitted from Clearity’s Steps Through OC program by receiving personalized Ovarian Cancer Counseling. Clearity … Read more
Accredited Program Data May Set Benchmark for Adult Cancer Survivor Care
July 9, 2024 9:00 amby Roman Fabbricatore
Fertility and sexual health services appear to be offered to cancer survivors less often than other services at CoC-accredited practices.
Enforcing survivorship standards may help centers provide services to address the needs of cancer survivors, according to … Read more
Program Helps Medically Underserved, Minority Cancer Survivors Be More Active
July 3, 2024 9:00 amby Linda Wang
Physical activity can have many benefits for cancer survivors, from improving their quality of life to potentially making it less likely that their disease will come back. Yet studies have shown that many cancer survivors struggle to … Read more
Study Supports More Inclusive Clinical Trials With Broader Eligibility Criteria —No difference in adverse events, clinical benefit, OS for patients with or without waivers
June 27, 2024 9:00 am by Charles Bankhead
Patients who received protocol waivers in a clinical trial of targeted anticancer therapy had outcomes similar to those who met all enrollment criteria, a large retrospective review showed.
Patients who received waivers had a clinical benefit rate … Read more
The best way to prevent this deadly cancer is to remove multiple organs. And I’m about to do it.
June 24, 2024 9:00 amClearity’s Perspective: This article is written by a daughter whose mother was diagnosed with advanced ovarian cancer. She shares the story of her mother’s diagnosis and treatment and how her family handled learning of her mother’s inheritable genetic condition. Clearity
Platinum-resistant ovarian cancer: mirvetuximab soravtansine benefits are maintained in patients who require dose modifications
June 20, 2024 9:00 amAs presented at the ESMO Gynaecological Cancers Congress 2024 (Florence, 20–22 June), a post-hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial in patients with high folate receptor alpha (FRalpha), platinum-resistant ovarian cancer revealed that even those who required … Read more
One Patient Changed This Oncologist’s View of Hope. Here’s How.
June 12, 2024 9:00 amBy Sharon Worcester, MA
CHICAGO — Carlos, a 21-year-old, lay in a hospital bed, barely clinging to life. Following a stem cell transplant for leukemia, Carlos had developed a life-threatening case of graft-vs-host disease.
But Carlos’ mother had faith.
“I … Read more
Achieving High-Quality Care for Patients With Ovarian Cancer
June 10, 2024 9:00 amClearity’s Perspective: This article highlights that some people with ovarian cancer who live in certain geographic locations, like rural areas, may get treated at centers with less experience treating ovarian cancer and/or fewer resources to support whole-person needs. Clearity offers … Read more
Dual Immunotherapy Improves Response Rates in Gynecologic Clear Cell Cancers
June 4, 2024 9:00 amby Wayne Kuznar
CHICAGO — Clinical activity and survival outcomes improved with the addition of ipilimumab (Yervoy) to nivolumab (Opdivo) in patients with ovarian or other gynecologic clear cell carcinomas, according to results from the non-comparative phase II BrUOG 354 … Read more
No Benefit to Adding Atezolizumab to Chemo/Bevacizumab for Ovarian Cancer
June 2, 2024 9:00 amby Silas Inman
The addition of atezolizumab (Tecentriq) to single-agent non–platinum-based chemotherapy and bevacizumab (Avastin) did not provide any additional benefits for patients with recurrent ovarian cancer, according to the final analysis of the phase 3 AGO-OVAR 2.29/ENGOT-ov34 study (NCT03353831) … Read more
Advanced Ovarian Cancer: Can Lymphadenectomy Be Avoided for Some Patients?
June 2, 2024 9:00 amby The ASCO Post Staff
Some people with advanced epithelial ovarian cancer may safely avoid having their lymph nodes removed during surgery without it impacting their survival outcomes, helping to reduce the risk of postoperative complications. This research was presented … Read more
Estrogen-Only Hormone Therapy Linked to Increased Gynecologic Cancer Risk, But Estrogen-Progestin Combination Therapy Lowers It
June 1, 2024 9:00 amby Aaron Tallent
Key Points:
- Hormone replacement therapy (HRT) can reduce bothersome symptoms of menopause, but there is concern it may increase the incidence of certain cancers.
- An analysis from the Women’s Health Initiative shows that estrogen-only HRT may increase